Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPA plus statin vs statin alone for vascular aging in adults ≥45 years
ChiCTR2600118798Phase 4Not yet recruiting
- Sponsor
- Shanxi Bethune Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Epadel in vascular ageing (VA) and hypertriglyceridemia (2 arms), sponsored by Shanxi Bethune Hospital. Primary endpoint: Carotid-femoral pulse wave velocity (cfPWV) at 12 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Epadel
03
Conditions
vascular ageing (VA)hypertriglyceridemia
Beyond the preview
Go deeper on ChiCTR2600118798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118798.